Literature DB >> 29754673

Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial.

Andrew P Ambrosy1, Ankeet S Bhatt2, Amanda L Stebbins3, Lisa M Wruck3, Marat Fudim2, Stephen J Greene2, William E Kraus2, Christopher M O'Connor4, Ileana L Piña5, David J Whellan6, Robert J Mentz7.   

Abstract

BACKGROUND: Despite more than 200 years of clinical experience and a pivotal trial, recently published research has called into question the safety and efficacy of digoxin therapy in heart failure (HF).
METHODS: HF-ACTION (ClinicalTrials.gov Number: NCT00047437) enrolled 2331 outpatients with HF and an EF ≤35% between April 2003 and February 2007 and randomized them to aerobic exercise training versus usual care. Patients were grouped according to prevalent digoxin status at baseline. The association between digoxin therapy and outcomes was assessed using Cox proportional hazard and inverse-probability weighted (IPW) regression models adjusted for demographics, medical history, medications, laboratory values, quality of life, and exercise parameters.
RESULTS: The prevalence of digoxin therapy decreased from 52% during the first 6 months of enrollment to 35% at the end of the HF-ACTION trial (P <0.0001). Study participants were 59± 13 years of age, 72% were male, and approximately half had an ischemic etiology of HF. Patients receiving digoxin at baseline tended to be younger and were more likely to report New York Heart Association functional class III/IV symptoms (rather than class II) compared to those not receiving digoxin. Patients taking digoxin had worse baseline exercise capacity as measured by peak VO2 and 6-min walk test and greater impairments in health status as reflected by the Kansas City Cardiomyopathy Questionnaire. The association between digoxin and the risk of death or hospitalization differed depending on whether Cox proportional hazard (Hazard Ratio 1.03, 95% Confidence Interval 0.92-1.16; P = .62) or IPW regression models (HR 1.08, 95% CI 1.00-1.17; P = .057) were used to adjust for potential confounders.
CONCLUSION: Although digoxin use was associated with high-risk clinical features, the association between digoxin therapy and outcomes was dependent on the statistical methods used for multivariable adjustment. Clinical equipoise exists and additional prospective research is required to clarify the role of digoxin in contemporary clinical practice including its effects on functional capacity, quality of life, and long-term outcomes.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29754673      PMCID: PMC7050977          DOI: 10.1016/j.ahj.2018.02.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  30 in total

1.  Sex-based differences in the effect of digoxin for the treatment of heart failure.

Authors:  Saif S Rathore; Yongfei Wang; Harlan M Krumholz
Journal:  N Engl J Med       Date:  2002-10-31       Impact factor: 91.245

2.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Authors:  Ali Ahmed; Michael W Rich; Thomas E Love; Donald M Lloyd-Jones; Inmaculada B Aban; Wilson S Colucci; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2005-12-08       Impact factor: 29.983

3.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

Authors:  Kirkwood F Adams; Gregg C Fonarow; Charles L Emerman; Thierry H LeJemtel; Maria Rosa Costanzo; William T Abraham; Robert L Berkowitz; Marie Galvao; Darlene P Horton
Journal:  Am Heart J       Date:  2005-02       Impact factor: 4.749

4.  Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure.

Authors:  Steven J Keteyian; Mahesh Patel; William E Kraus; Clinton A Brawner; Timothy R McConnell; Ileana L Piña; Eric S Leifer; Jerome L Fleg; Gordon Blackburn; Gregg C Fonarow; Paul J Chase; Lucy Piner; Marianne Vest; Christopher M O'Connor; Jonathan K Ehrman; Mary N Walsh; Gregory Ewald; Dan Bensimhon; Stuart D Russell
Journal:  J Am Coll Cardiol       Date:  2016-02-23       Impact factor: 24.094

5.  Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.

Authors:  Kirkwood F Adams; J Herbert Patterson; Wendy A Gattis; Christopher M O'Connor; Craig R Lee; Todd A Schwartz; Mihai Gheorghiade
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

6.  Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure.

Authors:  M Gheorghiade; V Hall; J B Lakier; S Goldstein
Journal:  J Am Coll Cardiol       Date:  1989-01       Impact factor: 24.094

7.  Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale.

Authors:  David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña
Journal:  Am Heart J       Date:  2007-02       Impact factor: 4.749

8.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.

Authors:  Mihai Gheorghiade; William T Abraham; Nancy M Albert; Barry H Greenberg; Christopher M O'Connor; Lilin She; Wendy Gattis Stough; Clyde W Yancy; James B Young; Gregg C Fonarow
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

9.  Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators.

Authors:  M Gheorghiade; J St Clair; C St Clair; G A Beller
Journal:  J Am Coll Cardiol       Date:  1987-04       Impact factor: 24.094

10.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.

Authors:  Mihai Gheorghiade; Gregg C Fonarow; Dirk J van Veldhuisen; John G F Cleland; Javed Butler; Andrew E Epstein; Kanan Patel; Inmaculada B Aban; Wilbert S Aronow; Stefan D Anker; Ali Ahmed
Journal:  Eur Heart J       Date:  2013-04-16       Impact factor: 29.983

View more
  1 in total

Review 1.  Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF).

Authors:  Riya R Parikh; Khushbu R Patel; Joseph V Pergolizzi; Frank Breve; Peter Magnusson
Journal:  Cureus       Date:  2022-03-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.